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Abstract: 
Introduction: Non-surgical management of older women with ER positive, operable breast cancer is 
common in the UK with up to 40% of over 70s receiving primary endocrine therapy.  Whilst this may 
be appropriate for frailer patients, for some it may result in treatment failure, contributing to the 
poor outcomes seen in this age group. Wide variation in the rates of non-operative management of 
breast cancer in older women exists across the UK. Case mix may explain some of this variation in 
practice.  
Methods: Data from two UK regional cancer registries were analysed to identify whether variation in 
treatment observed between 2002 and 2010 at hospital and clinician level persisted following 
adjustment for case mix. Expected case-mix adjusted surgery rates were derived by logistic 
regression using the variables age, proxy Charlson Co-morbidity Score, deprivation quintile, method 
of cancer detection, tumour size, stage, grade and nodal status. 
Results: Data on 17154 women over 70 with ER+ operable breast cancer were analysed. There was 
considerable variation in rates of surgery at both hospital and clinician level. Despite adjusting for 
case mix, this variation persisted at hospital level, although not at clinician level. 
Conclusion:  This study demonstrates variation in selection criteria for older women for operative 
treatment for early breast cancer, meaning that some older women may be under or over treated 
and may partly explain the inferior disease outcomes associated with this age group.  It emphasises 
the urgent need for evidence based guidelines for treatment selection criteria in older women with 
breast cancer. 
(249/250 word) 
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Introduction. 
One third of all breast cancers occur in women over 70 years in the UK. With increasing age, levels of 
co-morbidity and frailty increase, resulting  in deaths from other causes  exceeding  breast cancer 
mortality in older women with breast cancer
(1, 2)
. Additionally, tolerance of some breast cancer 
therapies also decreases 
(3, 4)
. Consequently, older women with operable breast cancer may be 
offered alternative treatment schedules when compared to younger women 
(5-7)
. One such 
treatment strategy is primary endocrine therapy (PET), where for women with potentially operable, 
oestrogen receptor positive (ER+) cancers surgery may be omitted in favour of endocrine therapy 
alone. Primary endocrine therapy gained popularity in the 1980s for the management of older 
women after Tamoxifen was shown to be effective in this setting 
(8)
 and a succession of randomised 
controlled trials comparing its efficacy against surgery followed. A subsequent Cochrane review 
comparing PET with surgery in the over 70s demonstrated superior rates of local control with 
surgery but no difference in survival rates 
(9)
. However the studies included in the review were 
flawed by modern standards because tumour ER status was not always tested and the age range of 
included younger, healthy women.  Recent studies have advocated the use of PET only in the very 
old or frail 
(10)
 and the most recent NICE guidelines issued in 2009 state that PET should only be 
offered to patieŶts if ͞sigŶifiĐaŶt Đoŵorďidity preĐludes surgery͟, aŶd that age should Ŷot ďe a faĐtor 
in itself
(11)
. 
In the UK there is considerable variation in the non-operative management of women over 70
(12)
, 
with regional rates varying between 12 and 40% 
(13)
. However these studies did not adjust for case 
mix which may account for some of this variation. Similarly, variation in socio-economic status may 
also impact on levels of co-morbidity, education, screening uptake and stage at presentation which 
are all factors that may contribute to the treatment decision. Therefore it is important to correct for 
differences between populations by adjusting for patient and tumour characteristics to understand 
whether these explain variations in treatment. 
Several studies have used registry data to identify factors affecting the receipt of surgery in older 
breast cancer patients, but none have examined the variation in treatment assignment according to 
individual hospital and clinician level 
(7, 14, 15)
. The present study aimed to analyse UK practice in older 
women with operable, ER-positive breast cancer to establish whether the variation observed at 
hospital and clinician level persists following adjustment for the patient and tumour characteristics 
of the cases managed. 
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Methods. 
Records on new invasive breast cancers diagnosed in women aged 70 years and over between the 
years of 2002 and 2010 were acquired for two UK cancer registration regions (West Midlands, 
Northern and Yorkshire). Data on patient and tumour characteristics and deprivation were included. 
Deprivation was recorded as quintiles of the income domain of the English Indices of Multiple 
Deprivation 2010
(16), deriǀed froŵ the patieŶt’s postĐode. Data were also obtained from a linked, 
matched Hospital Episode Statistics (HES) dataset. Hospital Episode Statistics are a record-based 
system that collects data on all admissions, outpatient appointments and A&E attendances at NHS 
hospitals in England, including diagnostic codes
(17)
. A proxy Charlson Comorbidity Index 
(18)
 score 
(excluding cancer) was calculated for each patient using the diagnostic codes recorded for any in-
patient or day case hospital admission in the 18 months before diagnosis of their breast cancer. The 
cancer component of the Charlson Comorbidity Index was derived from the registry data, in a 
method consistent with other similar registry data analyses 
(14, 19)
. The Charlson Index includes the 
following co-morbidities: myocardial infarct, congestive cardiac insufficiency, peripheral vascular 
disease, dementia, cerebrovascular disease, chronic pulmonary disease, diabetes, liver disease, 
kidney disease, and other cancers. Higher scores indicate higher levels of comorbidity. 
Analyses were restricted to patients with operable, oestrogen receptor positive (ER+) disease at 
diagnosis.  Patients with oestrogen receptor negative (ER-) disease, metastatic disease at diagnosis 
or pre-invasive disease (ductal carcinoma in situ or pure Paget’s disease of the Ŷipple) were 
excluded. Patients who died within 91 days of diagnosis were also excluded from the analysis as they 
were likely to have had advanced disease or other terminal illness which would have influenced 
treatment decision making. Oestrogen receptor status was only recorded for 43.5% (n=10 429) of 
the population, due in part to this information not being routinely collected in the Northern & 
Yorkshire registry until 2009. However the completeness of data regarding receipt of hormone 
therapy was more comprehensive and reliably documented for these patients 
(13)
. As such, it was 
assumed that patients with unknown ER status who received hormone therapy were ER+ (as 
hormone therapy should only be used in these patients). Patients with unknown ER status who did 
not receive hormone therapy were assumed to be ER- and were excluded. 
Primary treatment was dichotomised as surgery or no surgery according to whether or not the 
patient had an episode of breast surgery recorded within 6 months of diagnosis, this cut-off was 
chosen in order to attempt to differentiate between those patients having neo-adjuvant endocrine 
therapy and those having surgery following failed PET. The proportion of patients undergoing 
surgery was calculated for each clinician and hospital. Only hospitals and clinicians that treated 10 or 
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more patients over the period studied were included in the analysis, (excluding 2.9% of hospitals and 
3.1% of clinicians) leaving 68 hospitals and 167 clinicians in the final analysis. The final number of 
patients included in the hospital analysis were 16 654, with 16 606 included in the clinician analysis. 
Multivariable logistic regression was used to estimate the probability of a woman undergoing 
surgical treatment based on patient level factors, including age, proxy Charlson co-morbidity score, 
level of socioeconomic deprivation, tumour detection method, size, grade, TNM stage and nodal 
status. Missing data on disease characteristics and co-morbidity was handled using the method of 
multiple imputation by chained equations (MICE)
(20)
 to produce 25 imputed data sets and combining 
the results
(21)
. Covariates with over 50% missing data, such as HER2 status, were not included in the 
regression models. 
Expected rates of surgical treatment were calculated for each clinician and hospital by summing the 
individual patient probabilities estimated from the logistic regression model. Risk adjusted rates of 
surgery were produced by dividing the observed rate by the expected rate for each clinician and 
hospital and multiplying this by the national rate
(22)
.  
Both unadjusted and adjusted rates of surgery at clinician and hospital level were displayed 
graphically as funnel plots to allow examination of the variability at each level and identification of 
outlying practice. Funnel plots contain two limits; under the hypothesis that treatment choice is 
randomly determined and independent of clinician or hospital, 95% of units would lie within the 
inner limits (2 standard deviations from the mean) and 99% within the outer limits (3 standard 
deviations from the mean). 
Logistic regressions were performed in IBM SPSS Statistics version 21 and multiple imputations were 
performed using the open source statistical programming language R (version 3.0.1), with the 
remaining data handling and analysis performed in Microsoft Excel for Windows 7. 
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Results. 
Cancer registration records were obtained for 23 960 patients over the age of 70 years diagnosed 
with invasive breast cancer between the years 2002 and 2010. After applying the exclusion criteria 
(as described above) 17 129 records remained for analysis (see Figure 1). On the basis of the 
assumptions made to define ER status, it was estimated that 77% of women with non-metastatic 
disease had ER+ tumours. This is lower than observed in previous cohort studies;  for example Diab 
et al
(1)
 reported 90% of women over 75 diagnosed with breast cancer in the US had ER+ disease.  
The median age of the included population was 79 years (70-103 years). Of the 17 129, 9 955 were 
treated with surgery, giving an overall rate of 58.1%. Once again this is in keeping with other 
published data from the UK 
(13)
. Patient and disease characteristics are shown in Table 1. The 
proportion of older women being treated with surgery varied with patient and disease 
characteristics, with a woman being more likely to undergo surgery if she was younger, living in a 
less deprived area, having fewer or no co-morbidities, presenting through screening and having a 
smaller, node negative, Stage I or grade III cancer.  
The unadjusted rates of surgery varied substantially between hospitals (Figure 2(a)) and clinicians 
(Figure 3(a)), with 25 of 68 (36.8%) hospitals and 36 of 167 (21.6%) clinicians falling outside of the 
outer 99% limits, and 39 of 68 hospitals (57.4%) and 73 of 167 (43.7%) clinicians falling outside of the 
inner 95% limits on the funnel plots, meaning that they statistically differ from the expected norms. 
Taking account of patient level characteristics and adjusting for case mix did not significantly reduce 
the variation in surgery rates between hospitals, with 15 of 68 (22.1%) still falling outside of the 
outer 99% limits and 30 of 68 (44.1%) falling outside of the inner 95% limits on the funnel plot 
(Figure 2(b)). 
However, at clinician-level, adjusting for case mix did appear to reduce the variation in surgery rates, 
with 7 of 167 (4%) falling outside of the outer 99% limits and 17 of 167 (10.2%) falling outside the 
inner 95% limits on the funnel plot (Figure 3(b)).  
 
 
 
 
 
7 
 
Discussion. 
Between 2002 and 2010, 17 129 women were treated for assumed operable, ER+ breast cancer in 
the West Midlands and Northern & Yorkshire cancer registration regions. This represents a quarter 
of all breast cancer cases in the UK and the populations covered by these registries are 
demographically representative of the UK as a whole, making it reasonable to extrapolate these 
findings to the UK population generally. Of these, 9 955 were treated surgically, with the remaining 7 
174 (41.8%) having non-surgical management – this figure is in keeping with the rate of PET for 
these two registration regions in previous studies
(13)
. 
The analysis demonstrates that increasing age at diagnosis is associated with a reduced likelihood of 
receiving surgical treatment which is consistent with other similar studies 
(5, 15, 23-26)
. Deprivation level 
was also associated with treatment type, with the most deprived group being less likely to undergo 
surgical management, a finding also described by Lavelle and colleagues in their prospective cohort 
of 800 women 
(26)
. This may be due to the fact that affluence is associated with lower levels of 
comorbidity and smoking, and greater longevity and education 
(27)
, thereby promoting better health 
and discussion of treatment options. Higher levels of comorbidity were also associated with non-
surgical treatment, which is also consistent with other published studies, where co-morbidity is 
stated as a major reason for choosing PET over surgery 
(28-30)
. Tumour factors were also associated 
with treatment type, with larger, node positive tumours being less likely to be treated surgically 
which may represent patients and clinicians trying to avoid more major surgery, such as mastectomy 
and axillary node clearance. These results corroborate and update those found by Lavelle and 
colleagues in their study of 23 038 women aged 65 years and over between 1997 and 2005
(14)
.  
There was considerable variation in the rates of surgical treatment across the 68 hospitals and this 
variation persisted, despite case-mix adjustment, with 44.1% of units remaining outside the 95% 
limits in funnel plot analysis. Sixteen hospitals had significantly higher and 14 hospitals had 
significantly lower rates of surgery than could be explained by the case mix information available. 
There was also substantial variation in rates of surgical treatment between 167 clinicians, although 
this variability lessened with case-mix adjustment, with only 10.2% falling outside the 95% limits on 
funnel plot analysis. However, this still showed that 12 clinicians had significantly higher and 4 had 
significantly lower rates of surgery than could be explained by case mix alone. It should be noted 
that there were much smaller numbers available for analysis at clinician level and so these results 
are less reliable than the hospital level data. It is also possible that the persistence of variability in 
treatŵeŶt at hospital leǀel ďut Ŷot at ĐliŶiĐiaŶ leǀel is a result of a ͞Đluster effeĐt͟ – in that clinicians 
working within the same hospital are likely to have trained locally, will work together within a multi-
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disciplinary team and may subscribe to a local protocol, thereby having similar practices, resulting in 
magnified effect at hospital level when the data from individuals is combined.  
This persistence of variation in the treatment of older women with operable, ER+ breast cancer at 
hospital level is due to factors not included in the case-mix adjustment. One possible cause is 
clinician preference for either treatment. Current guidelines on the use of PET in the older breast 
cancer population state it should only be used in patients with a short life expectancy (less than 2-3 
years), when significant comorbidities preclude surgery, or in patients who refuse surgery
(11, 31)
. It is 
left to the treating clinicians’ judgement as to which patients should be offered PET as an alternative 
treatment option to surgery. Patient preference or refusal of surgery is also often stated as a 
possible reason for variation in treatment, which may reflect clinician preference and how the 
treatment options are presented, as was proposed by Hamaker et al 
(32)
. Qualitative research in this 
older group of patients has suggested that they are more passive decision-makers, relying on the 
advice of healthcare professionals 
(33, 34)
. Lavelle and colleagues found, in their cohort of 800 women 
over the age of 70, that lower rates of surgery among elderly patients are unlikely to be due to 
patient choice 
(26)
. 
Cancer registration data allows analysis of large cohorts of women treated in everyday, normal 
clinical practice. The routine nature of data collection through hospital coding teams makes this type 
of observational data less prone to selection bias. However, this method is hampered by missing 
data and potential coding inaccuracies which is a limitation of this study. A strength of this analysis is 
the use of multiple imputation which is less prone to bias than other commonly used methods to 
account for missing data, such as complete case analysis or inclusion of missing as a category in 
factor variables 
(35)
. However, whilst exploratory analysis of the imputed data suggested that the 
values were plausible, it is not possible to verify the extent to which the distribution of the imputed 
data accurately represents that of the missing values. By using 25 imputations, uncertainty around 
the missing data is incorporated into the probabilities used to adjust for case mix which mitigates 
against any small biases due to problems with the imputation model. Despite this model containing 
many clinically-relevant variables, not all covariates could be included due to missing data, e.g. HER2 
and progesterone receptor (PR) status. Additionally, assumptions had to be made regarding the ER 
status of the patients, with the resulting proportion of ER+ patients in the population being 
considerably smaller that reported in other studies 
(1)
 indicating that some eligible patients may have 
been missed from the analysis. However, we do not anticipate that this would affect the main 
findings of this analysis. 
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Another limitation of this analysis is the proxy Charlson score using HES data. Data are only available 
from HES if a patient who has had a hospital in-patient or day case admission in the year preceding 
their cancer diagnosis and relies heavily on coding of the relevant co-morbidities, and the accuracy 
of coding within HES 
(36)
. This method may under-score patients who have chronic co-morbidities 
which are well-controlled and managed in the community or outpatient setting, such as diabetes or 
dementia, as these alone are unlikely to precipitate a hospital admission. 
The case-mix adjustment may also have been inadequate, due to lack of data on important 
covariates, such as frailty, which are not captured by cancer registration data. Detailed data on every 
aspect of a patient’s care that could influence treatment choice cannot be collected in this setting, 
so factors such as frailty, patient choice, family input, social circumstances and clinician preference 
have not been included but may all play a part when deciding on a treatment modality in the elderly 
population. It is therefore possible that some other variables are confounding the results presented 
in this analysis. 
Many factors influence treatment choice, as discussed above and examining how these vary in 
relation to treatment may provide evidence to help explain the variability in treatment of older 
patients across the UK. Whilst this study has identified outlying practice, it is not clear why they are 
out-with normal practice, nor whether this outlying practice is unreasonable. Outlying status could 
be explained by data quality or confounders as previously discussed. However this variation should 
not be ignored, but further research to determine why they vary significantly should be undertaken. 
This study demonstrates that whilst the majority of UK hospitals and clinicians have similar decision 
making practices, there are some units where practice varies substantially from this norm and is not 
compensated for by case mix adjustment. Such significant variation in practice is important, 
particularly in view of the literature on this topic suggesting that patients who are treated with PET 
may have inferior rates of local control
(9)
 if selected poorly such that they were fit enough for 
surgery from the outset.  It also suggests that in some units, very frail and unfit women who would 
be adequately managed non-surgically, may be having surgery unnecessarily with its attendant 
morbidity.  This highlights the urgent need for evidence based guidelines for decision making in this 
age group. 
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